Discounted Cash Flow (DCF) Analysis Unlevered

Hyloris Pharmaceuticals SA (HYL.BR)

13.84 €

-0.06 (-0.43%)
All numbers are in Millions, Currency in USD
Stock DCF: -554,829.06 | 13.84 | overvalue

Operating Data

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 0.210.090.090.183.1020.68138.17923.096,166.7641,197.54
Revenue (%)
EBITDA -3.57-5.38-1.67-5.57-10.59-535.82-3,579.56-23,913.51-159,756.10-1,067,263.15
EBITDA (%)
EBIT -3.64-5.47-4.98-6.15-10.73-705.28-4,711.65-31,476.58-210,281.76-1,404,803.83
EBIT (%)
Depreciation 0.070.093.310.580.14169.461,132.107,563.0750,525.67337,540.68
Depreciation (%)

Balance Sheet Data

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Total Cash 0.282.690.2164.4150.541,726.8611,536.4477,070.11514,872.943,439,649.12
Total Cash (%)
Account Receivables ----------
Account Receivables (%)
Inventories ----------
Inventories (%)
Accounts Payable 1.772.062.871.592.62299.321,999.6413,358.7489,244.10596,202.24
Accounts Payable (%)
Capital Expenditure -2.80-0.03-1.23-0.62-1.06-127.84-854.07-5,705.68-38,117.23-254,645.17
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 13.84
Beta 0.568
Diluted Shares Outstanding 25.83
Cost of Debt
Tax Rate -2.63
After-tax Cost of Debt 4.52%
Risk-Free Rate
Market Risk Premium
Cost of Equity 6.383
Total Debt 12.29
Total Equity 357.52
Total Capital 369.81
Debt Weighting 3.32
Equity Weighting 96.68
Wacc

Build Up Free Cash

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 0.210.090.090.183.1020.68138.17923.096,166.7641,197.54
EBITDA -3.57-5.38-1.67-5.57-10.59-535.82-3,579.56-23,913.51-159,756.10-1,067,263.15
EBIT -3.64-5.47-4.98-6.15-10.73-705.28-4,711.65-31,476.58-210,281.76-1,404,803.83
Tax Rate 1.74%4.42%7.07%0.00%-2.63%2.12%2.12%2.12%2.12%2.12%
EBIAT -3.57-5.23-4.62-6.15-11.01-690.31-4,611.68-30,808.71-205,820.01-1,374,996.75
Depreciation 0.070.093.310.580.14169.461,132.107,563.0750,525.67337,540.68
Accounts Receivable ----------
Inventories ----------
Accounts Payable -0.290.81-1.271.03296.701,700.3211,359.1075,885.36506,958.13
Capital Expenditure -2.80-0.03-1.23-0.62-1.06-127.84-854.07-5,705.68-38,117.23-254,645.17
UFCF -6.31-4.89-1.74-7.47-10.91-352-2,633.34-17,592.22-117,526.21-785,143.10
WACC
PV UFCF -331.07-2,329.57-14,637.80-91,976.08-577,928.33
SUM PV UFCF -687,202.85

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 6.32
Free cash flow (t + 1) -800,845.97
Terminal Value -18,538,101.06
Present Value of Terminal Value -13,645,529.91

Intrinsic Value

Enterprise Value -14,332,732.76
Net Debt -37.72
Equity Value -14,332,695.03
Shares Outstanding 25.83
Equity Value Per Share -554,829.06